当前位置: X-MOL 学术Mol. Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
Molecular Cancer ( IF 37.3 ) Pub Date : 2020-01-30 , DOI: 10.1186/s12943-020-1144-6
Daixi Ren 1, 2, 3 , Yuze Hua 1, 2, 3 , Boyao Yu 1, 2, 3 , Xin Ye 2 , Ziheng He 2 , Chunwei Li 2 , Jie Wang 2 , Yongzhen Mo 2 , Xiaoxu Wei 2 , Yunhua Chen 2 , Yujuan Zhou 1 , Qianjin Liao 1 , Hui Wang 1 , Bo Xiang 1, 2, 3 , Ming Zhou 1, 2, 3 , Xiaoling Li 1, 2, 3 , Guiyuan Li 1, 2, 3 , Yong Li 4 , Zhaoyang Zeng 1, 2, 3 , Wei Xiong 1, 2, 3
Affiliation  

Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a variety of tumors, but resistance during treatment is a major issue. In this review, we describe the utility of PD-L1 expression levels, mutation burden, immune cell infiltration, and immune cell function for predicting the efficacy of PD-1/PD-L1 blockade therapy. Furthermore, we explore the mechanisms underlying immunotherapy resistance caused by PD-L1 expression on tumor cells, T cell dysfunction, and T cell exhaustion. Based on these mechanisms, we propose combination therapeutic strategies. We emphasize the importance of patient-specific treatment plans to reduce the economic burden and prolong the life of patients. The predictive indicators, resistance mechanisms, and combination therapies described in this review provide a basis for improved precision medicine.

中文翻译:

对PD1 / PD-L1的抗性潜在的预测性生物标志物和机制可阻断癌症免疫治疗。

靶向PD-1 / PD-L1的免疫检查点封锁在多种肿瘤中均具有良好的治疗效果,但治疗期间的耐药性是一个主要问题。在这篇综述中,我们描述了PD-L1表达水平,突变负担,免疫细胞浸润和免疫细胞功能在预测PD-1 / PD-L1阻断疗法疗效中的作用。此外,我们探讨了由PD-L1在肿瘤细胞上表达,T细胞功能障碍和T细胞衰竭引起的免疫治疗抗性的潜在机制。基于这些机制,我们提出了联合治疗策略。我们强调针对患者的治疗计划对于减轻经济负担和延长患者寿命的重要性。预测指标,抵抗机制,
更新日期:2020-01-31
down
wechat
bug